Now showing items 1-6 of 6
Liver Metastasectomy and Systemic Therapy Improve Overall Survival Compared With Surgery Alone After Curative Liver Resection of Colorectal Metastases in a Developing Country (Costa Rica)
Background Resection of liver-isolated metastases of colorectal cancer (CRC) offers the greatest likelihood of cure. Nevertheless, recurrence rates after this procedure are high, and chemotherapy is a reasonable choice ...
Neoadjuvant Metformin Added to Systemic Therapy Increases Pathological Complete Response in Breast Cancer: A Cross-sectional Study, Mexico Hospital, Costa Rica
Background: Metformin shows anti-proliferative effect on tumor cells. We studied the effect of metformin on achieving complete pathological response (pCR) in breast cancer patients receiving neoadjuvant therapy in a Latin ...
Androgen Receptor Expression in Locally Advanced Breast Cancer Predicts Lack of Pathological Complete Response After Neoadjuvant Treatment
Background: Data regarding the prognostic value of androgen receptor (AR) expression in locally advanced breast cancer (LABC) is limited. We aimed to determine the pathological complete response, defined as ypT0/is and ...
Sunitinib effectiveness and safety as first line treatment in metastatic renal cell carcinoma, in the Costa Rican population
Aim: Tyrosine kinase inhibitors are part of the armamentarium to treat metastatic renal cell carcinomas (mRCC). Costa Rica has approved sunitinib in the first line setting. The authors conducted a retrospective study to ...
Epidemiology and Outcomes of Bloodstream Infections in Patients With Solid Tumors in a Central American Population at Mexico Hospital, San Jose, Costa Rica
Purpose Bloodstream infections (BSIs) are an important cause of mortality in patients with solid tumors. We conducted a retrospective study to evaluate the epidemiologic profile and mortality of patients with solid tumors ...
Cyclin-dependent kinase 4/6 inhibitors as first-line treatment for post-menopausal metastatic hormone receptor-positive breast cancer patients: a systematic review and meta-analysis of phase III randomized clinical trials.
Background To compare the efficacy and toxicity of the combination of cyclin-dependent kinase 4/6 (CDK 4/6) inhibitors and nonsteroidal aromatase inhibitors (AI) versus AI alone as first-line therapy for patients with ...